Pharmaceutical marketing plan case study

9/5/2015 Pharmaceutical Marketing Plan Case Study
http://www.guerrillamarketer.com/pharmaceuticalmarketingplancasestudy/ 2/303
advertisement

Pharmaceutical Marketing Plan Case Study
Disclaimer: I created this Pharmaceutical Marketing Plan Case Study for local
pharmaceutical company in Egypt couple of years ago. All the data presented in this case
study are real and practical but might become not relevant to the current status of the product
because the plan was created couple years ago. The challenges and level of details explained
in this article would be really valuable to Master Marketing Planning and see how a complete
Marketing Plan looks like.
Also, there is no right or wrong in marketing, the more you practice the better you get. So try
to take the following Pharmaceutical Marketing Plan Case Study as a Start to see how full
the
internet
for
FREE
as
I
did
in
this
case
study!
Click
here
to
ENJOY
it:
http://www.guerrillamarketer.com/pharmaceutical-
marketing-
plan-
case-
study/
]

fledged marketing plan looks like.
This Pharmaceutical Marketing Plan Case Study created for DELPIRAMATE ® which
is antiepileptic and antimigraine Product, manufactured by Delta Pharma Company in Egypt,
it’s active ingredient is Topiramate. Here under the full Pharmaceutical Marketing Plan
Case Study I created for DELPIRAMATE:
1. Executive Summary:
Key issues, current position, potential overview of the outcome.
2. Corporate Strategy:
Mission, Vision and Value.
3. Macro/Micro Analysis:
PESTEL (External Audit), Internal Audit, Porter 5 Forces and SWOT.
4. Marketing Objectives:
Financial & Marketing Objectives.
5. Marketing Strategies:

Competitive Marketing Strategies, Segmentation, Targeting, Positioning.
6. Marketing Tactics:
Marketing Mix (7 P’s).
Implementation:
Tasks, resources, Budgeting, contingency plans.
7. Monitoring and control.
Let’s start the journey and enjoy full Pharmaceutical Marketing Plan Case Study …
1. Executive Summary: (Pharmaceutical Marketing Plan Case
Study)
DELPIRAMATE is antiepileptic and anti migraine Product.
DELPIRAMATE was positioned in Migraine and was prescribed in Epilepsy only.
The new product development strategy is to be positioned in Epilepsy as Main indication
(75%) and Migraine as Minor Indication (25%).
DELPIRAMATE Competitive Advantage Strategy is Cost Leadership and its double Scored
competitive advantage.

DELPIRAMATE in the Introductive Phase of the PLC and in Market Penetration Stage in
Ansoff’s Matrix, which need more investments to grow and proper control of pull and push
strategies.
DELPIRAMATE Market Share Units was 4.5 % in 2007, 8.5 % in 2008 and the Marketing
Objective is to be 15% in 2009 from Total Topiramate Market.
DELPIRAMATE Market Share (Units) in 2007 was 16.7%, in 2008 was 26% and the
Marketing Objective for 2009 is 41% from Total Topiramate 100mg Market.
DELPIRAMATE will achieve the expected Market Share in 2009 through proper management
of the Seven P’s consistently and effectively.
The Internal Communication factors are of great impact to achieve the DELPIRAMATE
Marketing Objectives in 2009.
2. Corporate Strategy: (Pharmaceutical Marketing Plan Case
Study):
2.1. DELTA PHARMA Vision:
Delta Pharma aims to be ranked within the top ten companies among the Arabian generic
pharmaceutical manufacturers in the coming ten years.
Development & innovation are our concerns to produce outstanding products required by
the medical professions.
2.2. DELTA PHARMA Mission:
What’s really needed versus what really exists is the equation that we commit ourselves to

achieve.
We therefore concentrate our main efforts in introducing & promoting products variety in
the pharmaceutical markets.
Our merciful thinking is to produce different medications for serious diseases to satisfy our
customers’ requirements.
Sharing interest & mutual cooperation with international research centers for technology
transfer of genetic medicines is one of our future strategies.
2.3. Delta Pharma Values:

:: INTEGRITY
All our actions & interactions reflect the highest quality because we provide the highest
[http://www.guerrillamarketer.com/wpcontent/uploads/2015/09/1.png]

standards of ethics & integrity.
:: Leadership
Good leadership using empowering, modeling leads to sustained superior performance .
:: Team work
We have found that to be a successful company we must let people to think, let them to
express themselves & to work with a team spirit.
:: Innovation
All tomorrow’s reality started with today’s great ideas. So no specific age or size, only
creativity is all we need.
:: Customer focus
We are responsible for identifying, anticipating and satisfying customer’s requirements. That’s
why you are always in our mind.
:: Community
Because your healthy life comes first, our mission is to operate a better place to live in.
:: Quality
Our mission is to produce products with the highest quality that will satisfy customer needs &
improve life.

3. Macro/Micro Analysis (Macro and Micro environmental
Audit): Pharmaceutical Marketing Plan Case Study


3.1.1. Political Factors affecting Macroenvironmental Analysis:
(Pharmaceutical Marketing Plan Case Study):
3.1.1.1. Stability Of Political System:
The political system in Egypt is stable since 28 February 1922 (from UK).
3.1.1.2.Taxation in Egypt:

In 2003, Egypt’s corporate tax rate was 40%, reduced to 32% for industrial companies, and
profits made through export operations. Branches of foreign companies are treated the same
as domestic companies. The government is planning to introduce a uniform corporate tax
structure.
Personal income tax is assessed according to a progressive schedule with rates from 5% to
25%. The standard deduction for a single person is E£2,000 (about $328).
The main indirect tax is the General Sales Tax (GST), set at 10% for most product, and 25 on
a few others. Services are taxed at lower rates of 5% and 10%. There are also stamp duties
that range from ranging from E£100 to E£600 (roughly, $15 to $100).
for more information: http://www.incometax.gov.eg/ [http://www.incometax.gov.eg/]
3.1.1.3.Employment Law:
Generally the Multinational Pharmaceutical Companies are having lower turnover than National
or Local Pharmaceutical Company.
To Reduce Our Turnover in N92: we should focus on the Internal communication within N92
and Satisfying our Internal Customers first.
The Internal Communication will be discussed in the marketing mix.
3.1.2. Economic factors affecting Macroenvironmental Analysis:

There is general world economic crisis allover the world but in Egypt, we didn’t affect yet
with that crisis.
The National Companies (as DELTA PHARMA) is likely effected than International or
Multinational Companies.
The Economic Price of DELPIRAMATE is better than all of the competing products, which
resulted in an opportunity of increasing its market share within the global economic crisis.
3.1.2.1. The Inflation Rate:
The Inflation rate in Egypt is high in comparison to USA or UK.
The inflation rate in Egypt is 18%. As you know by increasing the inflation rate, the
purchasing power decrease. But DELPIRAMATE isn’t affected yet because its economic price
is helping the patient to purchase the product.
3.1.2.2. GDP:
GDP Real Growth Rate: 6.9%.
GDP – per capita (PPP): 5,400 $.
Labor force: 24.72 million .
3.1.2.3. Unemployment rate: 8.7%.

Telephones – mobile cellular: 30.065 million, which means those customers are willing to pay
for Pharmaceutical Products.
3.1.2. Social Factors affecting Microenvironmental Analysis:
Egypt Population: 83,082,869 (July 2009 est.) .
Age Structure:
014 years: 31.4% (male 13,345,500/female 12,743,878) .
1564 years: 63.8% (male 26,823,127/female 26,169,421) .
65 years and over: 4.8% (male 1,701,068/female 2,299,875) (2009 est.)
Median Age:
total: 24.8 years
male: 24.4 years
female: 25.2 years (2008 est.).
Population growth rate: 1.642% (2009 est.).
3.1.3. Environmental Factors affecting Macroenvironmental Analysis:

DELPIRAMATE PRODUCT isn’t affected to the environmental changes as some pharmaceutical
products; hormones. Except the previous factor, the environmental changes aren’t affecting
the DELPIRAMATE efficacy or safety.
3.1.4. Legal Factors affecting Macroenvironmental Analysis:


3.2. Microenvironmental Analysis:
The Five changing dynamics For Micro Environmental Analysis.
Porter Five Forces.

SWOT Analysis.
3.2.1. The Five changing dynamics For Micro Environmental Analysis:
Business.
Competitors.
Suppliers.
Customers.
Stakeholders.
3.2.1.1. Business Factors affecting Micro Environmental Analysis:
3.2.1.1.1. Managerial Subfactors:
Delta Pharma Sales Pattern:

Neuropsychiatry Sector Rank:


[http://www.guerrillamarketer.com/wp-content/uploads/2015/09/67.png]


Organogram Of N92 Business Unit:


3.2.1.1.2. Competitive Subfactors:


3.2.1.1.2.1 Product Profile:


3.2.1.1.2.2 Product History:

3.2.1.1.2.2 Product History:
3.2.1.1.2.3 Indications:

3.2.1.1.2.3 Indications:

Common Indications:
In Epilepsy:
Monotherapy:
Newly diagnosed patients.
Conversion from another AED to DELPIRAMATE.
Add On Therapy:
Partial Onset Seizures.
Lennox Gastuat Syndrone.
Generalized Tonic Clonic Seizures.
In Migraine:
Prophylaxis of Migraine Headache.
3.2.1.1.2.4. Pharmacokinetics:

Metabolism:
The remainder is extensively metabolized by hydroxylation, hydrolysis, and
glucuronidation.
Six metabolites have been identified in humans, none of which constitutes more than 5%
of an administered dose.
3.2.1.1.2.5: Mechanism of Action:

Other side effects:
psychomotor slowing                                   4.1 %
memory problems                                       3.3 %
Fatigue                                                       3.3 %
Confusion                                                    3.2%
Somnolence (state of nearsleep)                  3.2 %

Notes:

RE=Refractory Epilepsy
RD=Recommended Dose
Precautions:
Patients with Renal or Hepatic Impairment, have a risk of Calculi information (especially in
predisposed patients). So hydration is recommended to reduce the risk.

Pregnancy:
Teratogenic effects ( in mice, rats and rabbits).
Calculate the Risk/Benefit Ration.
Lactation:
Excreted in Breast Milk.
Discontinue Nursing or the Drug.

Overdosing:
Symptoms of overdose may include but are not limited to:
seizures
dizziness, drowsiness, tiredness
agitation
depression
speech problems
blurred vision, double vision
troubled thinking
loss of coordination
inability to respond to things around you
loss of consciousness
confusion and coma
fainting
upset stomach and stomach pain
loss of appetite and vomiting
excessive hunger
shortness of breath; fast, shallow breathing

pounding or irregular heartbeat
muscle weakness
bone pain
A specific antidote is not available. Treatment is entirely symptomatic.
3.2.1.1.2.2 Competitive Marketing Intelligence:


3.2.1.1.2.3 Market Analysis:

The previous data shows that total Egyptian Market, Antiepileptic Market, Antimigraine
Market and Topiramate Market is growing, which is an opportunity for DELPIRAMATE to grow.

Topiramate® Market Analysis:
The Market Leader (Rx) is TOPIRAMATE.
Market Leader (Value) is TOPAMAX.

3.2.1.1.3. Financial Subfactors:
Delta Pharma; Neuropsychiatry Department is a great sector which have good financial
environment, and we always are looking for the best financial assists that can help us to get
the most of our Product Specialists.
Tips for enhancing the Financial Environment that N92 as:
Increasing Product Specialists Net Salary to 14001500 LE.
Facilitating Cars from the 1st month of Work; even if Company Cars not Own Cars.
Fuel Expenses or Transportation Expenses.
Clear Incentive Scheme to make the Product Specialist to make DELPIRAMATE the STAR in
the Market.
Other financial issues will be discussed in the Marketing Mix (People Part).
3.2.1.1.4. Technical Subfactors:
The great technical process always help the system to be step forward.
In Delta Pharma:

We Have ETMS (Electronic Territory Management System).
Providing Laptops for top management.
facilitating the Internet access for Office Managers.
Providing Professional email account for each employee in Delta Pharma.
Different types of electronic reports; marketing intelligence reports, weekly plan, weekly
reports…etc.
The Five changing dynamics For Micro Environmental Analysis:
Business.
Competitors.
Suppliers.
Customers.
Stakeholders.
3.2.1.3. Suppliers Factors affecting Micro Environmental Analysis:
DELPIRAMATE Supplier is to the Production factory in 10th Of Ramadan City.
DELPIRAMATE 100 mg is provided in enough quantities all over 20092010.
We have an issue in DELPIRAMATE 25 mg, if we can produce it, the results will be great
in penetrating the market very powerfully.
DELPIRAMATE have 8 distributors:

UCP (the main distributor).
Ibnsina.
Multipharma.
Egydrug.
Overseas.
EMIC.
Sofico.
Direct.
Sales Analysis of Distributors Performance:

Recommendations for better Distributors Management: For DELPIRAMATE, the most important

distributors are:
1.UCP.
2.Ibnsina.
3.Overseas.
Business.
Competitors.
Suppliers.
Customers.
Stakeholders.
3.2.1.4. Customers’ Factors affecting Micro Environmental Analysis:
Our Target Segment is Neuropsychiatry (NUNP) Doctors as main customers. More details will
be in Segmentation & Targeting Part.

3.2.1.4.1. Marketing Research:
I will conduct four marketing researches for DELPIRAMATE, each one conducted one
quarterly basis.
On each quarter, I will send Research Proposal for each one conducted for DELPIRAMATE.
The main tool in the 1st Year Of Marketing Researches is the Questionnaire, which will
contain quantitative and qualitative questions.
The main facility for executing the marketing researches is through roundtable discussions
as 1st target activity then Group meetings as contingency plan (in case of limited financial
resources).
The timelines as following:
1ST Marketing Research: MayJuneJuly.
2nd Marketing Research: AugustSeptemberOctober.
3rd Marketing Research: November – December Jan.
4th Marketing Research: FebMarchApril.
3.2.1.4.2. Customers Loyalty Program:
I will conduct four roundtable discussion on the year plan, all of the loyal customers (High

Potential and High Prescribed ) are invited at the 1st month of each quarter, to get the
maximum benefits from each one.
3.2.1.4.3. Marketing Communications:
To be discussed in the marketing mix.
Business.
Competitors.
Suppliers.
Customers.
Stakeholders.
3.2.1.5. Stakeholders’ Factors affecting Micro Environmental Analysis:

The External and Connected Stakeholders aren’t forming any risk on DELPIRAMATE,
considering the Internal Stakeholders:
Employees: also they aren’t having any power in Deciding the marketing dynamics in Delta
Pharma.
Managers: the senior and top management aren’t risky also on DELPIRAMATE Marketing
dynamics. But the following are the stakeholders that are controling the dynamics of

DELPIRAMATE:
1 Business Unit Director of Neuropschaitry Sector Of DELTA PHARMA (Dr. Mohammed
Refaat).
Dr. Mohie Hafez (CEO Of DELTA PHARMA).


Business.
Competitors.
Suppliers.
Customers.
Stakeholders.
Microenvironmental Analysis:
Porter Five Forces.
SWOT Analysis.
3.2.2. Porter Five Forces:


3.2.2.1. Threat Of Substitute:

There are no risk of Substitute Threat for DELPIRAMATE, as there are no herbal medicines
or complementary medicines that can provide the same efficacy as DELPIRAMATE.
Other Topiramate molecules, other antiepileptic or anti migraine molecule aren’t considered
as substitutes rather than direct and indirect competitioers.
3.2.2.2. Bargaining Power Of Buyers:
The Bargaining Power Of Buyer is helping the DELPIRAMATE to grow, as it’s the most
economic cost for the patient.
The following Pie chart shows that the market leader for Topiramate molecule is
TOPIRAMATE for all conc and for 100 mg conc.


3.2.2.3. Threat of Entry:

From the Previous Data, you can conclude that Topiramate Market is growing, so it’s a good
opportunity to enter a new products for different companies there.
opiramate market is contains one brand (original molecules) and 2 generic molecules, one
of them is the market leader, so upon release of new product with different conc. (25, 50,
100 mg) , you can predict that there is a great risk of entry competition if the conc. 25 mg
of DELPIRAMATE not released yet, as its help in stabilizing the penetration phase of
DELPIRAMATE molecule.
3.2.2.4. Bargaining Power Of Suppliers:

There are no Bargaining Power Of Suppliers for DELPIRAMATE. But considering the Bargaining
Power of Distributors, Delta Pharma is minimizing that power through:
Availability of Seven Distributors and One Direct Sales, no concentration of distributor.
Recruitment of Distributors Manager, who is directly responsible for dealing with sales
issues, returns and other problems with distributors.
High relationship with distributors especially Ibnsina.
Size of Purchases is coming with DELPIRAMATE side as it’s the most economic price for
Pharmacists, AlMona’saat and Military Hospitals.
There are no switching costs for distributors as most of them getting the same % of Product
discount. Some Bonuses may differs in different quarters as promotional incentives for
Pharmacists.
3.2.2.5. Rivalry Among Existing Competitors:
Antiepileptic Market is Growing 4.8% PPG in 2008 than 2007.
Antimigraine Tiptan Market is growing 5.2 % PPG in 2008 than 2007.
Topiramate Market is growing for the 3 competitive products in 2008 than 2007 by 16%,
73%, 31% for TOPAMAX, TOPIRAMATE and DELPIRAMATE respectively.
The following charts illustrate some important conclusions about TOPIRAMATE MARKET.

Porter Five Forces.
SWOT Analysis.
3.2.3. SWOT Analysis:

3.2.3. SWOT Analysis:

The Objective Of S.W.O.T. Analysis for DELPIRAMATE:
The strengths and Weaknesses are representing where is DELPIRAMATE now, while the
Opportunities and Threats are representing where the DELPIRAMATE can go in the future.
S.W.O.T. Strategies for DELPIRAMATE:
Strengths
Strong Portfolio for DELPIRAMATE supported by Strong Company Portfolio; DELTA PHARMA.
Sales Of DELTA PHARMA YTD Oct. 2008 = 96,895,500.
Sales Of Neuropsychiatry Sector Oct. 2008 = 21,709,264.
PPG % Units MAT Nov. 2008 = 31.4%.
Strong Management Team for N92.
Good financial resources to sponsor KOLs, participation in conferences exhibitions,
roundtable activities and group meetings.
Distribution Manager for managing all of the issues for distributors sales.
Weaknesses:
Lack of 25 mg conc.

No Clear Detail Aid for DELPIRAMATE.
No Clear Product Positioning.
High Workforce Turnover (16% of total PS in N92).
Low Net Salary for P.S. in a comparison with Multinational Companies.
No Financial Director.
Low Internal Communication (will be enhanced through the new BUM.
Opportunities
The willing of management team to invest for this Product; considering the detail aid and
promotional tools.
New Positioning for DELPIRAMATE for 100mg (as main indication for switching the current
patient, addon therapy, or refractory cases) which acquire 100 mg rather than the new
cases for 25 mg.
Threats:
New generic products with 25, 100 mg will easier than DELPIRAMATE unless the release of
25 mg.
Competitive Marketing Activities of Janssen Cilag and Sabaa Companies.
The Global world Economic Crisis if reached Egypt will affect the sales generally although
DELPIRAMATE the most economic one in Topiramate Market

Porter Five Forces.
SWOT Analysis.
[http://www.guerrillamarketer.com/wp-

4. Marketing Objectives: (Pharmaceutical Marketing Plan Case
Study):
[http://www.guerrillamarketer.com/wp-
content/uploads/2015/09/2.png]

The following data shows how I built the Marketing Objectives for DELPIRAMATE:

Summary of the financial Marketing Objectives:
The Marketing Objectives Set is matching the Growth Rate of All Topiramate 100 mgs
comparative analysis and All Topiramate Molecules.
The Marketing Objectives set, was based on the growth rate got from IMS from 2007 and
2008.
The Topiramate Market, antiepileptic market, anti migraine Triptan market, Total
Neuropsychaitry Market and Total Egyptian Market is growing, which give the DELPIRAMATE
a great opportunity to pass from Introductory phase to growth phase.
Qualitative Marketing Objectives:
1.Completing all of the Marketing Communication Tools within the 1st Quarter of Activating my
work 15th of April till 15th of June. The main Marketing Communication Tools are:

The Detail Aids; Binder for Epilepsy and Migraine indications.
Finishing the Medical Articles campaigns.
Making one roundtable Discussion in a Reputable Place for KOLs.
Managing the Promotional Campaigns with Field force.
Managing the Marketing Campaigns in Neuropsychiatry Conferences.
Managing the Group Meetings for Product Specialists.
2.Four Marketing Researches in four quarters from my starting work, each one held on each
quarter.
3.Minimizing the internal customers (Employees in N93) turnover through continous
developmental programs in a coordination with the Business Unit Director.

4. Increasing the employees quality of delivering DELPIRAMATE messages, analyzing the sales
results, managing distributors, improving the frequency of visits and minimizing the gaps
between planning and execution.
5. Increasing the learning environment for N92 employees through continuous delegations
and assignments.
6. Maximizing the Other qualitative objectives will be explained in the people part of Marketing
Mix.
Barriers for Implementation of the Marketing Objectives:
High Employees turnover in N92 (15% of the headcount).
Lack of good internal communication due to top managerial changes.
Lack of Topdown learning environment for Product Specialists except the employees who
were working with Dr. Mefreh.
Lack of Clarifying the Sales objectives in matching the Organization Vision and Strategy.
Low disposable income for Product Specialists in a comparison to Multinational Companies,
which results in their transient performance till they find new opportunities.
Lack of Transportation Expenses till the delivery of Cars.
Delaying the Salaries of Product Specialists till the 1st week of each month.
The Policy of Under balance; the product specialist get part of the salary till he passed three
months in the company, which results in loosing their enthusiasm and loyalty.

The Policy of Under balance; the product specialist get part of the salary till he passed three
months in the company, which results in loosing their enthusiasm and loyalty.
Low Financial Coordination in prepaid booking system for hotels; in Traveling Region out of
Cairo for Field Force Activates or Group Meetings.
Delaying the delivery of finance prepaid for group meetings (this item considering the
Product Specialists).
5. Marketing Strategies:(Pharmaceutical Marketing Plan Case
Study):

5.1. Competitive Marketing Strategy for DELPIRAMATE:
Competitive Advantage Strategy.
Growth Strategy.
Marketing Positioning Strategy.
5.1.1. Competitive Advantage Strategy (Porter’s Generic Strategy):

DELPIRAMATE is acting through the unique marketing strategy, which is the Cost Leadership
Competitive Marketing Strategy.
We can’t act though differentiation and cost leadership, otherwise our product won’t get a
competitive advantage strategies in the market. E.g. from Market Communication;
ITESALAT in its launch stage, as it was acting in differentiation and cost leadership, so they
stuck in the middle. But Mobinil acting though Cost Leadership and Vodafone acting though
differentiation Strategy.
5.1.2. Growth Strategy (Ansoff’s Matrix):

Justification beyond Ansoff’s Matrix:
From the following PLC, you can understand that DELPIRAMATE in in the introduction phase
(which is Market Penetration), while TOPIRAMATE and TOPAMAX are in the Growth Phase
(which are moving from Market Penetration to Market Development)

5.1.3. Marketing Positioning Strategy:
The Positioning Strategy is the Strategy that N92, Neuropsychiatry and Delta Pharma as a

whole company should adapt. This strategy isn’t including DELPIRAMATE as N92 and
Neuropsychiatry Sector and Delta Pharma.

Competitive Marketing Strategy for DELPIRAMATE:
Competitive Advantage Strategy.
Growth Strategy.
Marketing Positioning Strategy.

5.2. Segmentation, Targeting and Positioning:
For TOPAMAX in 2007 and 2008.
For TOPIRAMATE in 2008.
For DELPIRAMATE in 2008.
The Statistics are based on Prescriptions Index: MAT Sept. 2007, and MAT Sept. 2008.


Segmentation and Targeting Of Total Country for Physicians:
5.2.1. Segmentation and Targeting Per Manager:


X1 = Giza Regions (Dokki, Agoza, Mohandeseen, Sahafyeen, Faisal, Giza, Haram, Manial,
Badrasheen, Sayeda Zeinab, Half Of Down Town, Azhar, Abdeen, Half Of Down Town,
Badrasheen, Sayeda Zeinab, Maadi, Helwan, Masr El Adeema).
X2= Cairo Regions (East, Zatoun, Ain Shams, Shobra & Shobra ElKhima, ElMataryah, El
Zaher, Abbasia, Bab ElShehriah, 2/3 Of Heliopolis, 2/3 of Shobra & Shobra ElKhima, 1/3
Heliopolis, Rood El Farag).
X3= Alex1, Alex2, Behera, and Kafr ElShikh.
X4= Domiat, Ismalia, Port Said, Mansoura, Meat Gamr, Aga, Dekernas, Manzala,
Simbelawyeen, Belkas, Sherbeen, Mattaria, Abu El Azayem, Abu Hammad, Abu Kebeer, Al
Zakazik, Suez, Kaluibia.
X5= Basyon, Santa, Kafr El Zayat, ElMahala, Sammanoud, Tanta, Zefta, Menofia.
X6= Upper Egypt (Aswan, Quena, Sohag, Beni Suif, Fayoum, Asuiot).
5.2.2. Segmentation and Targeting Per Specialty/Manager:


5.2.3. Segmentation and Targeting Per Specialty/Manager:

Opportunities:
From IMS data MAT Nov. 2008:
TOPAMAX Sales = 47,000 Unit.
TOPIRAMATE Sales = 53,500 Unit.
So the Market Leader in Units is TOPIRAMATE.
But from IMS Prescription Index MAT Sept. 2008:
TOPAMAX = 28,318 Rx.
TOPIRAMATE = 4,651 Rx.
So the Market Leader in Rx and Units should be TOPAMAX.
This means the Product have been replaced through the Pharmacist, because of more
economic price of the Generic; TOPIRAMATE and means that Product Specialists of

TOPAMAX aren’t visiting the Pharmacies frequently.
Frequent Sales Campaigns to Pharmacies and Key Pharmacies, we can achieve a High Market
Share and Sales (in Units) because the most economic Product is DELPIRAMATE.

Out Great Opportunity to Cover:
1.CARIO / GIZA with full field force man power.
2. Upper Egypt.
The previous data was in 2007, so If we have recent data of IMS, will be GREAT Opportunity to
monitor the Marketing Dynamics in Egypt Territories.
6. Marketing Tactics (Marketing Mix) or 7 P’s :


6.1. Promotion (Marketing Communications):
[http://www.guerrillamarketer.com/wp-content/uploads/2015/09/1.jpg]

Marketing Communications tools for DELPIRAMATE:
Pull & Push Strategy
Branding
Marketing Communication Mix
6.1.1. Pull & Push Strategy:

Key Account Management (KAM):
It’s considered as Unstable Business because:
The business dynamics of the A.M. Accounts is changing.
There is a Power of Place (Power Of A.M. Accounts): which require special discounts,
bonuses, different from season to another.
The Purchases are affected by Place (Account) Budget, so there is instability in this
business.
The key customers (Doctors) are focused, so there is a power of controlling the business
which affected by satisfying their business needs.
The companies are competing together in this market, so the account get the best offer
accompanied by services; discounts, bonuses, ethical services…etc.
Because all other previous six factors, it makes this market changing, so the CASH COW of
this market isn’t sustainable (if we achieved a high market share there).

Product Specialists’ Distributors Management: DELPIRAMATE is distributed thought:
UCP.
IBNSINA.
OVERSEAS.
EGYDRUG.
MULTIPHARMA.
SOFICO.
EMIC.
UCP and IBN SINA is representing almost 50% of Distributing our Products to Pharmacies for
both sales Representatives and Telesales.
EGYDRUG, and PHARMAOVERSEAS need to be targeted through TeleSales only.
Each Product Specialist responsible for:
Visiting the Top 2 Distributors Sales in his Region.

Follow up with telesales and sales rep for each distributor, and pushing DELPIRAMATE
Product to Pharmacies (as I show in the GREAT OPPORTUNITY Part of Marketing
Strategies; the TOPAMAX Rx is replaced by TOPIRAMATE through Pharmacists Power).
Product Specialists’ Distributors Relationships Management:
The Product Specialist should have a very good relationship with:
The Branch Manager of the Distributor.
– National Sales Manager Of the Distributor.
– Sales Supervisor of the region that P.S. promote DELPIRAMATE in.
–Telesales Supervisor (for the region that P.S. promote DELPIRAMATE in).
– Sales Representative in his Region.
– Telesales (that promote DELPIRAMATE in his region).
Important Keys for Pharmacies Management:
We need to get the electronic data of Sales / Pharmacy from the potential distributors
(especially UCP) twice monthly to:
To Track the sales for top 15 pharmacies.

Taking correcting actions for each pharmacy.

Pharmacies Management:
Each Product Specialist responsible for:
1. Give us data about Top 15 Pharmacies in his Region. Send us Report every 2 weeks about:
– Stock.
– Consumption Pattern.
– New orders.
2. Selling DELPIRAMATE to TOP 15 Pharmacies with the 1 sales Rep./Distributor/Weekly.
The P.S. should know who is the Sales Rep. that cover most of his Region.
Each P.S. should go in a double visit with Sales Rep. to top 15 Pharmacies weekly.


Field Visits:
From the doctors’ List, every Product Specialist should cover his doctors’ List frequency:
each Product Specialist list should vary from 80 to 120 doctor.
Always Rx are increasing the Growth Rate Of DELPIRAMATE and help in CASH COW in the
later growth phases of the product.
How To Make DELPIRAMATE Adopted by the Customer?

2 & 3. Brand Awareness & Brand Attitude:
This is could be assessed through Qualitative and Quantitative Marketing Research.
In Roundtable Discussion, or Group Meetings: the Discussion Guide may be contains:
Perceptual Map/Positioning Map : to assess the Price/Quality.
Brand Celebrities Map.
Questionnaires.
For Assessing Brand Attitude:
This could be achieved through Emarketing, as we can assess the doctor behavior when
browsing our website; what are the most common concerns, what are the 1st issues attracted
their attention.
For Achieving Brand Awareness:
– Marketing Campaign to announce DELPIRAMATE website, asking the doctors emails to send
them our weekly or monthly newsletters.

4. Brand Purchase Intention:
DELPIRAMATE Purchase Intention means that is the customer intended to purchase
DELPIRAMATE by name?
Is the customer asking about DELPIRAMATE in Pharmacies?
Is the Pharmacists are asking about DELPIRAMATE in Distributors?
This is could be assessed through:
Quantitative Assessment: through a questionnaire distributed for Pharmacists to assess
about the patient behavior in purchasing the DELPIRAMATE.
Qualitative Assessment: through the relationship between Product Specialist and
Pharmacists. The assessment tool done through personal observation (by our Product
Specialist in 23 hours in the pharmacy as a campaign for this objective).
5. Purchase Facilitation:
Purchases is facilities through DELPIRAMATE availability in the market.
Purchase Facilitation is achieved through managing the Push Strategy of DELPIRAMATE.


Marketing Communications tools for DELPIRAMATE:

Pull & Push Strategy
Branding
Marketing Communication Mix
DELPIRAMATE Branding:
Please note the following branding ideas are built in the 1st few weeks of building the
marketing plan, so the below are preliminary ideas before getting briefed to advertising
agencies and before the concept of digital marketing and MultiChannel Marketing developed
as well:
I will Create Binder that contains 2 parts:
1st Part for Epilepsy.
2nd Part for Migraine.
The Binder Personality is Cake like shape to represent the double Scored shape. The Binder
will be launched at the Start Of August 2009.Considering the typography, design, color, slogan
an identity will be proposed open the approval of this Marketing Plan.
Here under the summary of DELPIRAMATE Marketing Communications Mix:
Marketing

Communication
Mix
1. Personal
Selling
Implementation
Date
1.1. Doctors’
Visits
Four – Six Visits of
the Target
Segments/day
1.2. Pharmacies
Visits
15 top
Pharmacy/Week
1.3.
Distributors
Visits
2
Distributors/Week
2. A.M.+ P.M.
Activities
Target Segment Implementation Dates
2.1. Group
Meetings
2.1.1. Universities
1 Group Meeting / 2
Months /University/P.S.
2.1.2. Key 1 Group Meeting / 2

Hospitals Months /Hospital/P.S.
2.1.3. Military
Hospitals
1 Group Meeting / 2
Months /Hospital/P.S.
2.1.4. Police
Hospitals
1 Group Meeting / 2
Months /Hospital/P.S.
2.1.5. Distributors
1 Group Meeting / 3
Months /Distributor/P.S.
2.2. Roundtable
Activities
KOLs (P.M.) for
DELPIRAMATE
One
Roundtable/Quarter/Target
Segment
KOLs Of All
University Staff
around Egypt
Key A.M.+ P.M.
Pharmacists
3. Promotional
Tools
Promotional Tools Implementation Date:

3.1. DELPIRAMATE
Binder
Launched On Start Of
August 2009
3.2. Dose Cards
August 2009
3.3. Giveaways
(Pens, Gifts) and
Gimmickx
September 2009
3.4. Folders
Jan.2010
4.
DELPIRAMATE
Club
Targeting Strategy
E-Marketing tools
E-Marketing
Activities
Marketing
Tactics
(Differentiated
Targeting Strategy)
4.1. DELPIRAMATE
CLUB for Doctors.
Website
4.(1+2).1. Online
Seminars
4.2. DELPIRAMATE 4.(1+2).2.

CLUB for
Pharmacists.
Yahoo Group for
DELPIRAMATE
Knowledge about
DELPIRAMATE
Facebook Group for
DELPIRAMATE
4.(1+2).3.
Knowledge about
Topiramate
E – Newsletters
4.(1+2).4. Online
Survey
DELPIRAMATE Club Card
4.
(1+2).5.Username
and Password on
the Website
A.
Announcements
about
DELPIRAMATE
B. E-Newsletters
C. Online
Conferences
and Seminars
D. Online
Surveys /

Questionaires
E. Prize Draws /
Quarter
4.3. DELPIRAMATE
Club for Patients
4.3.1. DELPIRAMATE Club
Card to get data about
Marketing
Database
For Loyal Patients
(Patients who
received
4.3.2. Epilepsy
Management
Getting their
database from
the doctors and
DELPIRAMATE
more than 1month
treatment)
4.3.3. Migraine
Management
we will contact
them for
delivering them
4.3.4. DELPIRAMATE
Efficacy
DELPIRAMATE
Club Card
4.3.5. Getting free samples
each month
4.3.6. Online Surveys

4.3.7. Prizes Draws /
Quarter
5. Patients’
Loyalty Scheme Marketing Tools Implementation Date
Money Off
Vouchers/Coupons.
August 2009.
Customer Loyalty
Bonus Scheme
Buy Three , Get
One Free
DELPIRAMATE Club
for Patients
6. Doctors’
Sponserships
(Conferences)
Not included in 2009 Budget
6.2. Product:

6.2. Product:

DELPIRAMATE Profile.
Characteristics Of DELPIRAMATE.
Elements Of DELPIRAMATE.
DEPIRAMATE Portfolio.
Product Life Cycle (P.L.C.).
DELPIRAMATE Portfolio Planning Tool:
Boston Consultancy Group (B.C.G.) Matrix.
Growth Strategy (Ansoff’s Matrix) for DELPIRAMATE.
New Product Development for DELPIRAMATE.
Product Adoption for DELPIRAMATE.
6.2.1. Product Profile:
Have been explained in the Micro Environmental Analysis.
6.2.2. Characteristics Of DELPIRAMATE:
6.2.2.1. Physical Characteristics:


6.2.2.2. Functional Characteristics:
[http://www.guerrillamarketer.com/wp-content/uploads/2015/09/12.jpg]

6.2.2.2. Functional Characteristics:

6.2.2.3. Physiological Characteristics:

6.2.3. DELPIRAMATE Elements:

DELPIRAMATE is containing all of the four elements for any Product Management:
DELPIRAMATE as a Core Product:
The active ingredient is : Sulfamate Substituted Monosaccharide.
DELPIRAMATE used for Epilepsy and Migraine Managements.
DELPIRAMATE as a Tangible Product:
Contains all the benefits that have been illustrated in Product Profile, and the DELPIRAMATE
pack that have been mentioned in Product Profile.
DELPIRAMATE as an Augmented Product:
(Pharmaceutical Marketing Plan Case Study)
DELPIRAMATE is containing a unique COMPETITIVE ADVANTAGE; the DOUBLE SCORED
FORM of DELPIRAMATE.

DELPIRAMATE is Potential Product:
DELPIRAMATE is the most economic Product in Topiramate Molecules, which make the patient
is willing to use it frequently (especially in Migraine) without any economic burden. Which
resulting in increasing the disposable income for the patient, so it provide him with potential
future advantages in saving more money for different life purposes.
6.2.4. DELPIRAMATE Portfolio:

The Product is distributed in all the Six Distributors who are distributing the Product in all
Egypt territories.
6.2.5. Product Life Cycle (PLC):


DELPIRAMATE is in the introduction Phase of the P.L.C.; Product Life Cycle.
In this stage the Sales grow but at a cost.
To make our Product moves fast to the growth phase, we need to invest and predict that
the profit isn’t going to cover the cost in this phase, until the product pass the Breakeven
point in the growth phase.
In this Phase, our Growth Strategy is Market Penetration; so we need to penetrate the
market very well with the new positioning and high workforce capabilities.
6.2.6. DELPIRAMATE Portfolio Planning Tool: Boston Consultancy Group (B.C.G.)

6.2.6. DELPIRAMATE Portfolio Planning Tool: Boston Consultancy Group (B.C.G.)
Matrix:
B.C.G. Matrix for Total Topiramate Molecules:
Nov. MAT 2008 RMS RMG
TOPAMAX 3.5 15.8
TOPIRAMATE 0.3 43.7
DELPIRAMATE 0.1 166.9

B.C.G. Matrix for Total Topiramate 100mgs Molecules:

Nov. MAT 2008 RMS RMG
TOPAMAX 100mg 2.7 13.9
TOPIRAMATE 100mg 0.4 46.9
DELPIRAMATE 0.2 166.9

6.2.7. Growth Strategy (Ansoff’s Matrix) for DELPIRAMATE:

6.2.8. Product Adoption for DELPIRAMATE:
New Product Development Tactics Of DELPIRAMATE:
1. Repositioning of DELPIRAMATE in:
Epilepsy (as Main Indication, by 75%).
– Migraine (as minor Indication, by 25%).
2. Showing the Competitive Advantage Of DELPIRAMATE:
Double Scored Competitive Advantage (100 mg contains 25 mg in the same pack).
– The Most economic Cost for the Patient.

6.3. Price:


The Pricing Strategy of DELPIRAMTA already have been set, non of the three competitive
products changed the Pricing Strategy in the last 2 years.

Pharmaceutical marketing plan case study

Pharmaceutical marketing plan case study

Recommended

Recommended

More Related Content

What's hot

What's hot (20)

Viewers also liked

Viewers also liked (9)

Similar to Pharmaceutical marketing plan case study

Similar to Pharmaceutical marketing plan case study (20)

Recently uploaded

Recently uploaded (20)

Pharmaceutical marketing plan case study